Anaptysbio (ANAB) Operating Income Growth (5y) (2021 - 2026)

Anaptysbio (ANAB) Operating Income Growth (5y) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,725.60 Bn 68,725.31 Bn -
2 Nanobiotix 1,953.19 Bn 1,953.13 Bn -
3 Akari Therapeutics 1,132.35 Bn 1,132.35 Bn -
4 BeOne Medicines 472.73 Bn 467.94 Bn 1.35 Bn
5 Vertex Pharmaceuticals 123.52 Bn 116.27 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.74 Bn 60.99 Bn 3.31 Bn
7 Belite Bio 63.09 Bn 63.09 Bn -
8 Argenx Se 56.42 Bn 51.24 Bn 1.41 Bn
9 Revolution Medicines 37.76 Bn 37.76 Bn -
10 Anaptysbio 1.58 Bn 1.30 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -13.53%
Dec 31, 2025 14.94%
Sep 30, 2025 27.93%
Jun 30, 2025 -2.94%
Mar 31, 2025 -21.85%
Dec 31, 2024 15.36%
Sep 30, 2024 7.58%
Jun 30, 2024 -8.63%
Mar 31, 2024 -11.24%
Dec 31, 2023 -16.47%
Sep 30, 2023 -17.44%
Jun 30, 2023 -22.73%
Mar 31, 2023 -23.02%
Dec 31, 2022 -29.43%
Sep 30, 2022 -26.67%
Jun 30, 2022 -61.19%
Mar 31, 2022 -26.02%
Dec 31, 2021 -57.90%
Sep 30, 2021 -44.46%
Jun 30, 2021 -17.35%